Merck KGaA Updates 2013 Guidance With 2014’s Targets
This article was originally published in The Pink Sheet Daily
Executive Summary
Quicker than expected cost-savings from its efficiency program improved the family-owned company’s overall financial outlook, but sales of best-selling product Rebif are still expected to decline in the second half of 2013 following launch of competing oral MS drugs.